MovDisordV3, PascalFrancis, Corpus, bibRecord, 003130

DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1

Identifieur interne : 003130 ( PascalFrancis/Corpus ); précédent : 003129; suivant : 003131

DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1

Auteurs : C. Sampaio ; J. J. Ferreira ; F. Simoes ; M. J. Rosas ; M. Magalhaes ; A. P. Correia ; A. Bastos-Lima ; R. Martins ; A. Castro-Caldas

Source :

Movement disorders [ 0885-3185 ] ; 1997.

RBID : Pascal:98-0015582

Descripteurs français

Pascal (Inist)
- Blépharospasme, Hémispasme facial, Toxine, Clostridium botulinum, Etude comparative, Traitement, Homme, Chimiothérapie, Equivalence, Forme pharmaceutique.

English descriptors

KwdEn :
- Blepharospasm, Chemotherapy, Clostridium botulinum, Comparative study, Dosage form, Equivalence, Hemifacial spasm, Human, Toxin, Treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 12`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1`
A11	`01`	`1`		`@1 SAMPAIO (C.)`
A11	`02`	`1`		`@1 FERREIRA (J. J.)`
A11	`03`	`1`		`@1 SIMOES (F.)`
A11	`04`	`1`		`@1 ROSAS (M. J.)`
A11	`05`	`1`		`@1 MAGALHAES (M.)`
A11	`06`	`1`		`@1 CORREIA (A. P.)`
A11	`07`	`1`		`@1 BASTOS-LIMA (A.)`
A11	`08`	`1`		`@1 MARTINS (R.)`
A11	`09`	`1`		`@1 CASTRO-CALDAS (A.)`
A14	`01`			`@1 Institute of Pharmacology and General Therapeutics, Faculty of Medicine, University of Lisbon @2 Lisbon @3 PRT @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon @2 Lisbon @3 PRT @Z 2 aut. @Z 9 aut.`
A14	`03`			`@1 Department of Neurology and Neurosurgery, S. Joao Hospital @2 Porto @3 PRT @Z 3 aut. @Z 8 aut.`
A14	`04`			`@1 Department of Neurology, St. António Hospital Porto @3 PRT @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 1013-1018`
A21				`@1 1997`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000069474290250`
A44				`@0 0000 @1 © 1997 INIST-CNRS. All rights reserved.`
A45				`@0 16 ref.`
A47	`01`	`1`		`@0 98-0015582`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02C`
C03	`01`	`X`	`FRE`	`@0 Blépharospasme @5 01`
C03	`01`	`X`	`ENG`	`@0 Blepharospasm @5 01`
C03	`01`	`X`	`SPA`	`@0 Blefaroespasmo @5 01`
C03	`02`	`X`	`FRE`	`@0 Hémispasme facial @5 04`
C03	`02`	`X`	`ENG`	`@0 Hemifacial spasm @5 04`
C03	`02`	`X`	`SPA`	`@0 Hemiespasmo facial @5 04`
C03	`03`	`X`	`FRE`	`@0 Toxine @5 07`
C03	`03`	`X`	`ENG`	`@0 Toxin @5 07`
C03	`03`	`X`	`SPA`	`@0 Toxina @5 07`
C03	`04`	`X`	`FRE`	`@0 Clostridium botulinum @2 NS @5 08`
C03	`04`	`X`	`ENG`	`@0 Clostridium botulinum @2 NS @5 08`
C03	`04`	`X`	`SPA`	`@0 Clostridium botulinum @2 NS @5 08`
C03	`05`	`X`	`FRE`	`@0 Etude comparative @5 16`
C03	`05`	`X`	`ENG`	`@0 Comparative study @5 16`
C03	`05`	`X`	`GER`	`@0 Vergleich @5 16`
C03	`05`	`X`	`SPA`	`@0 Estudio comparativo @5 16`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`06`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`07`	`X`	`FRE`	`@0 Homme @5 20`
C03	`07`	`X`	`ENG`	`@0 Human @5 20`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`08`	`X`	`FRE`	`@0 Chimiothérapie @5 23`
C03	`08`	`X`	`ENG`	`@0 Chemotherapy @5 23`
C03	`08`	`X`	`SPA`	`@0 Quimioterapia @5 23`
C03	`09`	`X`	`FRE`	`@0 Equivalence @5 24`
C03	`09`	`X`	`ENG`	`@0 Equivalence @5 24`
C03	`09`	`X`	`SPA`	`@0 Equivalencia @5 24`
C03	`10`	`X`	`FRE`	`@0 Forme pharmaceutique @5 35`
C03	`10`	`X`	`ENG`	`@0 Dosage form @5 35`
C03	`10`	`X`	`SPA`	`@0 Forma farmacéutica @5 35`
C07	`01`	`X`	`FRE`	`@0 Clostridiaceae @2 NS`
C07	`01`	`X`	`ENG`	`@0 Clostridiaceae @2 NS`
C07	`01`	`X`	`SPA`	`@0 Clostridiaceae @2 NS`
C07	`02`	`X`	`FRE`	`@0 Clostridiales @2 NS`
C07	`02`	`X`	`ENG`	`@0 Clostridiales @2 NS`
C07	`02`	`X`	`SPA`	`@0 Clostridiales @2 NS`
C07	`03`	`X`	`FRE`	`@0 Bactérie`
C07	`03`	`X`	`ENG`	`@0 Bacteria`
C07	`03`	`X`	`SPA`	`@0 Bacteria`
C07	`04`	`X`	`FRE`	`@0 Oeil pathologie @5 37`
C07	`04`	`X`	`ENG`	`@0 Eye disease @5 37`
C07	`04`	`X`	`SPA`	`@0 Ojo patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Paupière pathologie @5 38`
C07	`05`	`X`	`ENG`	`@0 Eyelid disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Párpado patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Système nerveux pathologie @5 45`
C07	`06`	`X`	`ENG`	`@0 Nervous system diseases @5 45`
C07	`06`	`X`	`SPA`	`@0 Sistema nervioso patología @5 45`
C07	`07`	`X`	`FRE`	`@0 Mouvement involontaire @5 46`
C07	`07`	`X`	`ENG`	`@0 Involuntary movement @5 46`
C07	`07`	`X`	`SPA`	`@0 Movimiento involuntario @5 46`
N21				`@1 364`

Format Inist (serveur)

NO :	PASCAL 98-0015582 INIST
ET :	DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1
AU :	SAMPAIO (C.); FERREIRA (J. J.); SIMOES (F.); ROSAS (M. J.); MAGALHAES (M.); CORREIA (A. P.); BASTOS-LIMA (A.); MARTINS (R.); CASTRO-CALDAS (A.)
AF :	Institute of Pharmacology and General Therapeutics, Faculty of Medicine, University of Lisbon/Lisbon/Portugal (1 aut.); Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon/Lisbon/Portugal (2 aut., 9 aut.); Department of Neurology and Neurosurgery, S. Joao Hospital/Porto/Portugal (3 aut., 8 aut.); Department of Neurology, St. António Hospital Porto/Portugal (4 aut., 5 aut., 6 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 6; Pp. 1013-1018; Bibl. 16 ref.
LA :	Anglais
CC :	002B02C
FD :	Blépharospasme; Hémispasme facial; Toxine; Clostridium botulinum; Etude comparative; Traitement; Homme; Chimiothérapie; Equivalence; Forme pharmaceutique
FG :	Clostridiaceae; Clostridiales; Bactérie; Oeil pathologie; Paupière pathologie; Système nerveux pathologie; Mouvement involontaire
ED :	Blepharospasm; Hemifacial spasm; Toxin; Clostridium botulinum; Comparative study; Treatment; Human; Chemotherapy; Equivalence; Dosage form
EG :	Clostridiaceae; Clostridiales; Bacteria; Eye disease; Eyelid disease; Nervous system diseases; Involuntary movement
GD :	Vergleich; Aufbereiten
SD :	Blefaroespasmo; Hemiespasmo facial; Toxina; Clostridium botulinum; Estudio comparativo; Tratamiento; Hombre; Quimioterapia; Equivalencia; Forma farmacéutica
LO :	INIST-20953.354000069474290250
ID :	98-0015582

Links to Exploration step

Pascal:98-0015582

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1</title>
<author><name sortKey="Sampaio, C" sort="Sampaio, C" uniqKey="Sampaio C" first="C." last="Sampaio">C. Sampaio</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Pharmacology and General Therapeutics, Faculty of Medicine, University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ferreira, J J" sort="Ferreira, J J" uniqKey="Ferreira J" first="J. J." last="Ferreira">J. J. Ferreira</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simoes, F" sort="Simoes, F" uniqKey="Simoes F" first="F." last="Simoes">F. Simoes</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, S. Joao Hospital</s1>
<s2>Porto</s2>
<s3>PRT</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rosas, M J" sort="Rosas, M J" uniqKey="Rosas M" first="M. J." last="Rosas">M. J. Rosas</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Magalhaes, M" sort="Magalhaes, M" uniqKey="Magalhaes M" first="M." last="Magalhaes">M. Magalhaes</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Correia, A P" sort="Correia, A P" uniqKey="Correia A" first="A. P." last="Correia">A. P. Correia</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bastos Lima, A" sort="Bastos Lima, A" uniqKey="Bastos Lima A" first="A." last="Bastos-Lima">A. Bastos-Lima</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martins, R" sort="Martins, R" uniqKey="Martins R" first="R." last="Martins">R. Martins</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, S. Joao Hospital</s1>
<s2>Porto</s2>
<s3>PRT</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Castro Caldas, A" sort="Castro Caldas, A" uniqKey="Castro Caldas A" first="A." last="Castro-Caldas">A. Castro-Caldas</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0015582</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 98-0015582 INIST</idno>
<idno type="RBID">Pascal:98-0015582</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003130</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1</title>
<author><name sortKey="Sampaio, C" sort="Sampaio, C" uniqKey="Sampaio C" first="C." last="Sampaio">C. Sampaio</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Pharmacology and General Therapeutics, Faculty of Medicine, University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ferreira, J J" sort="Ferreira, J J" uniqKey="Ferreira J" first="J. J." last="Ferreira">J. J. Ferreira</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simoes, F" sort="Simoes, F" uniqKey="Simoes F" first="F." last="Simoes">F. Simoes</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, S. Joao Hospital</s1>
<s2>Porto</s2>
<s3>PRT</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rosas, M J" sort="Rosas, M J" uniqKey="Rosas M" first="M. J." last="Rosas">M. J. Rosas</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Magalhaes, M" sort="Magalhaes, M" uniqKey="Magalhaes M" first="M." last="Magalhaes">M. Magalhaes</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Correia, A P" sort="Correia, A P" uniqKey="Correia A" first="A. P." last="Correia">A. P. Correia</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bastos Lima, A" sort="Bastos Lima, A" uniqKey="Bastos Lima A" first="A." last="Bastos-Lima">A. Bastos-Lima</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martins, R" sort="Martins, R" uniqKey="Martins R" first="R." last="Martins">R. Martins</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, S. Joao Hospital</s1>
<s2>Porto</s2>
<s3>PRT</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Castro Caldas, A" sort="Castro Caldas, A" uniqKey="Castro Caldas A" first="A." last="Castro-Caldas">A. Castro-Caldas</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blepharospasm</term>
<term>Chemotherapy</term>
<term>Clostridium botulinum</term>
<term>Comparative study</term>
<term>Dosage form</term>
<term>Equivalence</term>
<term>Hemifacial spasm</term>
<term>Human</term>
<term>Toxin</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Blépharospasme</term>
<term>Hémispasme facial</term>
<term>Toxine</term>
<term>Clostridium botulinum</term>
<term>Etude comparative</term>
<term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Equivalence</term>
<term>Forme pharmaceutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SAMPAIO (C.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FERREIRA (J. J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SIMOES (F.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ROSAS (M. J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MAGALHAES (M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CORREIA (A. P.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BASTOS-LIMA (A.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MARTINS (R.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>CASTRO-CALDAS (A.)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Pharmacology and General Therapeutics, Faculty of Medicine, University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology and Neurosurgery, S. Joao Hospital</s1>
<s2>Porto</s2>
<s3>PRT</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, St. António Hospital Porto</s1>
<s3>PRT</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1013-1018</s1>
</fA20>
<fA21><s1>1997</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000069474290250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1997 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0015582</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Blépharospasme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Blepharospasm</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Blefaroespasmo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Hémispasme facial</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hemifacial spasm</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hemiespasmo facial</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Toxine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Toxin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Toxina</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Clostridium botulinum</s0>
<s2>NS</s2>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Clostridium botulinum</s0>
<s2>NS</s2>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Clostridium botulinum</s0>
<s2>NS</s2>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="GER"><s0>Vergleich</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Equivalence</s0>
<s5>24</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Equivalence</s0>
<s5>24</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Equivalencia</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Forme pharmaceutique</s0>
<s5>35</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Dosage form</s0>
<s5>35</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Forma farmacéutica</s0>
<s5>35</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Clostridiaceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Clostridiaceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Clostridiaceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Clostridiales</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Clostridiales</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Clostridiales</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Bactérie</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Bacteria</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Bacteria</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Oeil pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Paupière pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Eyelid disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Párpado patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>46</s5>
</fC07>
<fN21><s1>364</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 98-0015582 INIST</NO>
<ET>DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1</ET>
<AU>SAMPAIO (C.); FERREIRA (J. J.); SIMOES (F.); ROSAS (M. J.); MAGALHAES (M.); CORREIA (A. P.); BASTOS-LIMA (A.); MARTINS (R.); CASTRO-CALDAS (A.)</AU>
<AF>Institute of Pharmacology and General Therapeutics, Faculty of Medicine, University of Lisbon/Lisbon/Portugal (1 aut.); Department of Neurology, Faculty of Medicine, Santa Maria Hospital and University of Lisbon/Lisbon/Portugal (2 aut., 9 aut.); Department of Neurology and Neurosurgery, S. Joao Hospital/Porto/Portugal (3 aut., 8 aut.); Department of Neurology, St. António Hospital Porto/Portugal (4 aut., 5 aut., 6 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 6; Pp. 1013-1018; Bibl. 16 ref.</SO>
<LA>Anglais</LA>
<CC>002B02C</CC>
<FD>Blépharospasme; Hémispasme facial; Toxine; Clostridium botulinum; Etude comparative; Traitement; Homme; Chimiothérapie; Equivalence; Forme pharmaceutique</FD>
<FG>Clostridiaceae; Clostridiales; Bactérie; Oeil pathologie; Paupière pathologie; Système nerveux pathologie; Mouvement involontaire</FG>
<ED>Blepharospasm; Hemifacial spasm; Toxin; Clostridium botulinum; Comparative study; Treatment; Human; Chemotherapy; Equivalence; Dosage form</ED>
<EG>Clostridiaceae; Clostridiales; Bacteria; Eye disease; Eyelid disease; Nervous system diseases; Involuntary movement</EG>
<GD>Vergleich; Aufbereiten</GD>
<SD>Blefaroespasmo; Hemiespasmo facial; Toxina; Clostridium botulinum; Estudio comparativo; Tratamiento; Hombre; Quimioterapia; Equivalencia; Forma farmacéutica</SD>
<LO>INIST-20953.354000069474290250</LO>
<ID>98-0015582</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003130 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003130 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:98-0015582
   |texte=   DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1

DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri